Pharmaceuticals, Biotechnology and Life Sciences
BioPharmX Corporation has enrolled patients for its Phase 2b testing BPX-04, a new drug limited by U.S. law to investigational use, topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.
Shield Therapeutics got positive results from the AEGIS-H2H clinical trial which compared Feraccru (ferric maltol) to Ferinject (ferric carboxymaltose (FCM)), as Feraccru has demonstrated it is non-inferior to IV iron therapy in treating iron deficiency anaemia.
Biogen said Monday it will buy Nightstar Therapeutics, a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
Verona Pharma is aiming to start second part of Phase 2 trial to test ensifentrine DPI formulation in patients with moderate-to-severe COPD over one week of twice-daily treatment, it said after announcing positive data from part one of the trial.
Auden Mckenzie and Waymade have breached UK and EU competition law by entering into anti-competitive agreements in relation to the supply of hydrocortisone tablets in the UK.
Amryt Pharma can now enrol young Epidermolysis Bullosa (EB) patients between the ages of 21 days to 4 years old to test AP101 as a potential treatment.
Galderma’s Phase 3 “Perfect” 2 clinical trials of Trifarotene, an investigational drug, against acne, with 2,400 patients met all primary and secondary efficacy endpoints, the company said Thursday.
Heron Therapeutics said Wednesday that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for Cinvanti (aprepitant) injectable emulsion, for intravenous (IV) use.
darolutamide
Acurx Pharmaceuticals’ recently completed test showed that at well-tolerated doses ACX-362E reaches concentrations in the colon that are projected to be therapeutically relevant for patients with Clostridioides difficile infection (CDI).